申请人:Hoffmann-La Roche Inc.
公开号:US05969139A1
公开(公告)日:1999-10-19
The invention relates to new and known tricyclic dione derivatives of the general formula ##STR1## wherein W represents hydrogen or lower alkyl; X represents lower alkyl; Y represents NR1; R.sup.1 represents hydrogen, lower alkyl, lower alkoxycarbonyl or lower alkoxycarbonyl-lower alkyl; Z represents aryl or heteroaryl optionally substituted by one or more halo, cyano, nitro, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, COR.sup.2, OCOR.sup.2, CO.sub.2 R.sup.2, OR.sup.2, S(O).sub.n R.sup.2, NR.sup.2 R.sup.3, N(R.sup.4)COR.sup.5, Ar, Ar-lower alkyl, Het or Het-lower alkyl substituents and/or on adjacent carbon atoms by lower alkylenedioxy; R.sup.2, R.sup.3, R.sup.4 and R.sup.5 each individually represent hydrogen, lower alkyl, Ar, Ar-lower alkyl, Het or Het-lower alkyl substituents; or R.sup.2 and R.sup.3 together represent the group --CH.dbd.CH--CH.dbd.CH-- or --CH.dbd.N--CH.dbd.CH--; Ar represents aryl optionally substituted by one or more halo, lower alkyl, lower alkoxy or nitro substituents; Het represents heteroaryl optionally substituted by one or more halo, lower alkyl, lower alkoxy or nitro substituents; and n stands for 0, 1 or 2 and to their salts which are inhibitors of herpes simplex virus thymidine kinase.
该发明涉及一般式##STR1##的新型和已知的三环二酮衍生物,其中W代表氢或较低的烷基;X代表较低的烷基;Y代表NR1;R.sup.1代表氢、较低的烷基、较低的烷氧羰基或较低的烷氧羰基-较低的烷基;Z代表芳基或杂芳基,可选择地被一个或多个卤素、氰基、硝基、较低的烷基、卤代较低的烷基、较低的烷氧基、卤代较低的烷氧基、COR.sup.2、OCOR.sup.2、CO.sub.2R.sup.2、OR.sup.2、S(O).sub.nR.sup.2、NR.sup.2R.sup.3、N(R.sup.4)COR.sup.5、Ar、Ar-较低的烷基、Het或Het-较低的烷基取代,和/或在相邻碳原子上被较低的烷基二氧代取代;R.sup.2、R.sup.3、R.sup.4和R.sup.5分别独立地代表氢、较低的烷基、Ar、Ar-较低的烷基、Het或Het-较低的烷基取代;或R.sup.2和R.sup.3一起代表--CH.dbd.CH--CH.dbd.CH--或--CH.dbd.N--CH.dbd.CH--的基团;Ar代表芳基,可选择地被一个或多个卤素、较低的烷基、较低的烷氧基或硝基取代;Het代表杂芳基,可选择地被一个或多个卤素、较低的烷基、较低的烷氧基或硝基取代;n代表0、1或2,以及其抑制单纯疱疹病毒胸苷激酶的盐。